My case

One case. Still unfolding.

A personal account of appendiceal cancer, surgery, and decisions under uncertainty.

Context, not a treatment template

This is a patient-reported summary based on the records behind this notebook. It is deliberately broad to protect privacy. It is a snapshot of an unresolved postoperative decision, not a live medical record or a recommendation for another patient.

I was diagnosed with adenocarcinoma involving the appendix/cecal region after surgery for what appeared to be appendicitis. The primary site remains a question across the pathology reports. A later right hemicolectomy provided more information, including cancer in regional lymph nodes.

The hard part has been making decisions when the evidence does not line up neatly with the case. The tumor’s biology creates important treatment questions, but there is much less direct evidence for this combination of disease and setting than I would like.

My details, with uncertainty kept visible

FieldWhat the account supportsLimit or open question
DiagnosisAdenocarcinoma involving the appendix and adjacent cecum.Appendix versus cecal origin remains a question across the reports.
How it was foundSurgery for appendicitis led to a cancer diagnosis.This is a historical account, without identifying dates.
OperationsAppendix surgery with partial cecal resection, followed by right hemicolectomy.The two operations produced different specimens; their findings must stay separate.
Local extentThe initial report described involvement of the outer surface; the later specimen showed invasion into surrounding fat.Ask the team for one integrated stage across both operations.
Regional nodesCancer was found in regional lymph nodes after the second operation.Reports differ on the total number examined. Exact counts are omitted here.
StageDescribed as stage III following surgery.The integrated site/stage and uncertain later imaging need clinical reconciliation.
GradeModerately differentiated in one interpretation; poorly differentiated in another.These are different pathology readings, not a resolved final grade.
Mucinous featuresA specialist review described a substantial mucinous component.Other wording differs. An absent subtype label does not prove a nonmucinous tumor.
MarginsThe completion-colectomy report describes negative margins.Interpretations of the first operation’s margins differ; the outside review notes fragmentation.
Lymphovascular invasionNot identified in the original interpretation; identified in an outside review.This disagreement concerns the earlier specimen and needs reconciliation.
Mismatch repairLoss of MLH1 and PMS2 expression supports deficient mismatch repair (dMMR).A separate DNA-based MSI result is not established in this public account.
Inherited riskAn inherited cancer syndrome has not been established in this account.Tumor protein findings do not by themselves establish a germline diagnosis.
Postoperative imagingSome findings were described as postoperative changes versus possible implants.Possible implants are not confirmed spread. No personal probability is assigned here.
Next treatmentChemotherapy and immunotherapy approaches have been discussed.This account does not report a final treatment choice or a systemic-treatment outcome.

The side-by-side pathology comparison shows why review can change the working description. Original reports remain private. Dates, exact age, care-team names, treatment locations, and specimen identifiers are not published.

The sequence, without identifying dates

The first finding

Appendicitis led to an unexpected diagnosis.

The pathology from the first operation changed the question from surgical recovery to cancer staging and treatment.

More information

A second operation clarified the extent.

The right hemicolectomy identified involved regional lymph nodes. Earlier assumptions had to be updated.

A different treatment question

dMMR made immunotherapy relevant.

It also raised a harder question: which immunotherapy evidence applies after surgery for appendix cancer?

Still open

Review the evidence and resolve what changes the plan.

Second opinions, pathology review, imaging follow-up, and test coordination are part of the decision process.

What remains uncertain

Possible findings on postoperative imaging are not the same as confirmed spread. I am not publishing a percentage for the chance that an uncertain finding is cancer. A number created from assumptions would look more precise than the evidence supports.

Likewise, results from a colon-cancer trial are not my personal recurrence odds. They can inform a specialist discussion without answering it completely.

What I want this account to offer

I do not have a finished success story or a treatment formula. I have a growing set of ways to keep the facts straight, ask more useful questions, and protect time for life alongside the research.

The most transferable lesson is simple: make the next decision clear, then find the information that can actually change it.

About this note

Personal experience and organizational suggestions. Not a clinical protocol.